Search results
Cell and gene therapy companies trip at scalability hurdle
Pharmaceutical Technology via Yahoo Finance· 3 days agoSince then, major strides have been made in the cell therapy space. The first chimeric antigen...
FAS signalling pathway is crucial for CAR T cell persistence - Nature Reviews Immunology
Nature· 6 days agoChimeric antigen receptor (CAR) T cell therapies have revolutionized the treatment of B cell and other malignancies, but the limited persistence of CAR ...
Keto supplement may improve immunotherapy for prostate cancer
Futurity· 2 days agoAdding a pre-ketone supplement, a component of a high-fat, low-carb ketogenic diet, to a type of...
Alka Dwivedi
Time Magazine· 2 hours agoFind out why Alka Dwivedi is on the TIME100 Health list.
Novel T-cell engager, CDH17 X CD3 cabotamig (ARB202) continues to explore dosing in patients with...
The Grass Valley Union· 6 days agoThe DMC review confirms the safety risk profile of cabotamig being consistent with published T-cell engagers. SEATTLE, April 26, 2024 /PRNewswire/ -- Arbele ...
IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma -...
Benzinga· 2 days agoNEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB), a clinical-stage biopharmaceutical company advancing innovative gamma-delta T cell
Targeting myeloma essential genes using NOT Gated CAR T-cells, a computational approach - Leukemia
Nature· 2 days agoChimeric antigen receptor (CAR) T-cells have recently been demonstrated to be highly effective in the disease, but the survival curves are yet to plateau. Thus, on-target, off-tumour toxicity ...
Repertoire partners with Bristol Myers for autoimmune vaccines By Investing.com
Investing.com· 3 days agoRepertoire Immune Medicines, a biotech firm specializing in T cell targeted immune therapies, has...
Sylvester Cancer Adding Cellular Therapy to Its Arsenal Against Metastatic Melanoma
Newswise· 1 day agoPatients in South Florida with metastatic melanoma will soon have access to the first cellular ...
Astellas hitches a ride in Poseida's convertible for $50M cell therapy collaboration
FierceBiotech· 21 hours agoThe companies have signed an agreement, via Astellas’ subsidiary Xyphos Biosciences, to develop two...